Latest news and press releases about ALX Oncology Holdings Inc. (ALXO): earnings reports, analyst upgrades/downgrades, product launches, partnerships and regulatory filings. Stay updated on every market-moving event.
ALX Oncology Holdings Inc., a clinical-stage immuno-oncology company, focuses on developing therapies for cancer patients in the United States. The company’s lead product candidate is Evorpacept, a CD47 blocking therapeutic biologic development as a combination therapy with other anti-cancer agents, including ASPEN-06, under phase 2 clinical study for treating Gastric/GEJ cancer.
Price
| Price | $1.76 |
| Market Cap | $237M |
| Exchange | NASDAQ |
| Country | US |
Valuation Ratios
| Price / Book | 1.75 |
| EV / EBITDA | -0.50 |
| Dividend Yield | 0.00% |
Profitability
| Return on Equity | -391.42% |
| Return on Invested Capital | -261.95% |
| Return on Assets | -172.23% |
| Gross Margin | 0.00% |
| Operating Margin | 0.00% |
| Net Margin | 0.00% |
Related companies: ANNX · BCYC · GLUE · KYMR · NKTX · STOK · TNYA
Explore sector: Healthcare · Biotechnology
More sections of ALXO: Overview · Financials · Valuation · Statistics · Estimates · Technical · Ownership · Events
Discover more: Radar — undervalued stock signals · Investment Academy — learn to analyze stocks